Brief: Celltrion Inc To Halt European Clinical Trials For Covid-19 Inhalation Treatment Due To Virus' Rapid Change Into Endemic Status
27/06/2022 23:50
Celltrion Inc 068270.KS :
* CELLTRION INC: TO HALT EUROPEAN CLINICAL TRIALS FOR
COVID-19
INHALATION TREATMENT DUE TO VIRUS' RAPID CHANGE INTO ENDEMIC
STATUS
Source text for Eikon: ID:
Further company coverage: 068270.KS
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares